Get the Stockscreener App
0.2195
4.73%
-0.0109
Pre-market:
.22
0.0005
+0.23%
Cel-Sci Corp. stock is traded at $0.2195, with a volume of 896.96K.
It is down -4.73% in the last 24 hours and down -33.48% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$0.2304
Open:
$0.2336
24h Volume:
896.96K
Relative Volume:
0.61
Market Cap:
$18.47M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-0.4304
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
-12.20%
1M Performance:
-33.48%
6M Performance:
-79.68%
1Y Performance:
-88.01%
1-Day Range:
$0.2059
$0.236
1-Week Range:
$0.2059
$0.25
52-Week Range:
$0.2059
$2.39
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.2195 | 18.47M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan
CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa
Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register
CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com
CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga
CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan
CEL-SCI advances in head and neck cancer treatment study - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance
Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register
Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia
CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia
CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Armenian Reporter
CEL-SCI advances Multikine study for head and neck cancer - Investing.com
CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter
Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - Stock Titan
CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World
Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA
Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com
CVM: Fiscal Year 2024 Results - Research Tree
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
Personal Finance - Business Wire
Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World
Have A Relaxing Holiday Season - MENAFN.COM
Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):